| Literature DB >> 32539722 |
Xiaotong Wang1, Zhongyu Wang1, Bing Li2, Ping Yang1.
Abstract
BACKGROUND: Acute coronary syndrome (ACS) is a group of clinical syndromes associated with substantial morbidity and mortality rate. SYNTAX and SYNTAX II score used to be a reference for surgical selection of coronary revascularization and prognosis evaluation in patients with 3-vessel or left main artery disease. In addition, apoB/apoA1 is an important predictor of ACS risk. This study aims to assess the prognosis value of different kinds of SYNTAX score together with apoB/apoA1 in universal ACS patients (Regardless of ACS type, lesion location and vessel numbers).Entities:
Keywords: PCI; Prognosis; SYNTAX II score; SYNTAX score; apoB/apoA1
Year: 2020 PMID: 32539722 PMCID: PMC7294645 DOI: 10.1186/s12872-020-01562-6
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Comparison of clinical baseline data between SYNTAX low and medium/high risk group [n(%),M(P25--P75)]
| Item | Low-risk group | Medium/high risk group | ||
|---|---|---|---|---|
| n | 331 | 65 | ||
| Gender | Male | 224(67.7) | 50(76.9) | 0.140 |
| Female | 107(32.3) | 15(23.1) | ||
| In-hospital ventricular fibrillation | 1(0.3) | 0 | 1.000 | |
| In-hospital ventricular tachycardia | 2(0.6) | 1(1.5) | 0.417 | |
| In-hospital atrial fibrillation | 6(1.8) | 3(4.6) | 0.170 | |
| In-hospital heart failure | 52(15.7) | 18(27.7) | 0.021 | |
| Hypertension | 211(63.7) | 40(61.5) | 0.736 | |
| Diabetes | 62(18.7) | 17(26.2) | 0.171 | |
| CHD history | 61(18.4) | 10(15.4) | 0.559 | |
| Myocardial infarction history | 22(6.6) | 6(9.2) | 0.432 | |
| PCI history | 18(5.4) | 6(9.2) | 0.255 | |
| Smoking history | 192(58.0) | 35(53.8) | 0.535 | |
| Age(years old) | 58.84 ± 10.27 | 60.23 ± 9.83 | 0.340 | |
| BMI(kg/m2) | 25.37 ± 3.93 | 24.83 ± 4.39 | 0.349 | |
| Ejection fraction(%) | 58.87 ± 10.83 | 56.12 ± 10.90 | 0.103 | |
| ApoB/ApoA1 | High risk | 9(2.7) | 6(9.2) | 0.023 |
| Low risk | 322(97.3) | 59(90.8) | ||
| ApoB/ApoA1 | 0.91(0.71–1.04) | 0.94(0.76–1.05) | 0.152 | |
| TG(mmol/l) | 1.73(1.0–2.13) | 1.78(1.14–2.30) | 0.267 | |
| LDL-c(mmol/l) | 3.13(2.46–3.65) | 3.17(2.46–3.70) | 0.727 | |
| Non HDL-c(mmol/l) | 3.5(2.77–4.10) | 3.62(2.94–4.05) | 0.464 | |
| Hb(g/L) | 140.81(131–153) | 140.5(129–155) | 0.976 | |
| PLT(× 109/L) | 205.2(166–238) | 193.01(157.5–227.5) | 0.182 | |
| HCT(L/L) | 0.93(0.39–0.45) | 0.42(0.39–0.46) | 0.768 | |
| LM | 16(4.8) | 16(24.6) | < 0.001 | |
| PLAD | 216(65.3) | 55(84.6) | < 0.001 | |
| MLAD | 173(52.3) | 38(58.5) | 0.415 | |
| RCX | 224(67.7) | 56(86.2) | < 0.001 | |
| RCA | 267(80.7) | 59(90.8) | 0.052 | |
| RAM | 5(1.5) | 2(3.1) | 0.323 | |
| Number of lesions treated | 1.38 ± 0.66 | 1.55 ± 0.73 | 0.032 | |
| Number of stents implanted | 1.49 ± 0.90 | 1.59 ± 1.0 | 0.345 | |
| Maximum stent diameter(mm) | 3.32 ± 0.49 | 3.24 ± 0.46 | 0.134 |
Comparison of MACCE incidence at different time points between SYNTAX low and medium/high risk group [n(%)]
| Item | Low-risk group | Medium/high risk group | |
|---|---|---|---|
| MACCE events in hospital | 19(4.4) | 9(9.5) | 0.049 |
| MACCE events in 1 year | 55(12.9) | 22(23.2) | 0.011 |
| MACCE events in 3 years | 112(26.2) | 36(37.9) | 0.023 |
| MACCE events in 5 years | 150(35.1) | 41(43.2) | 0.142 |
| Cardiovascular death in hospital | 10(2.3) | 5(5.3) | 0.165 |
| Cardiovascular death in 1 year | 20(4.7) | 9(9.5) | 0.081 |
| Cardiovascular death in 3 years | 36(8.4) | 11(11.6) | 0.325 |
| Cardiovascular death in 5 years | 50(11.7) | 17(17.9) | 0.125 |
| New myocardial infarction in 1 year | 5(1.2) | 1(1.1) | 1.000 |
| New myocardial infarction in 3 years | 14(3.3) | 3(3.2) | 1.000 |
| New myocardial infarction in 5 years | 25(5.9) | 7(7.4) | 0.578 |
| Recurrent revascularization in 1 year | 15(3.5) | 2(2.1) | 0.750 |
| Recurrent revascularization in 3 years | 33(7.7) | 8(8.4) | 0.820 |
| Recurrent revascularization in 5 years | 49(11.5) | 13(13.7) | 0.547 |
| New/aggravated heart failure in 1 year | 5(1.2) | 5(5.3) | 0.021 |
| New/aggravated heart failure in 3 years | 19(4.4) | 7(7.4) | 0.293 |
| New/aggravated heart failure in 5 years | 24(5.6) | 8(8.4) | 0.303 |
| New stroke in 1 year | 4(0.9) | 1(1.1) | 1.000 |
| New stroke in 3 years | 11(2.6) | 3(3.2) | 0.727 |
| New stroke in 5 years | 19(4.4) | 4(4.2) | 1.000 |
Comparison of EQ-5D score at different time points between SYNTAX low and medium/high risk group [M(P25-P75)]
| Item | Low-risk group | Medium/high risk group | |
|---|---|---|---|
| EQ-5D score in hospital | 10.77(9.25–13.68) | 11.03(9.40–13.82) | 0.974 |
| EQ-5D score in 1 year | 12.99(12.23–14.52) | 13.23(12.24–14.50) | 0.677 |
| EQ-5D score in 5 years | 12.76(12.16–14.44) | 12.88(12.16–14.44) | 0.993 |
Comparison of clinical baseline data among SYNTAX II low, medium and high-risk group [n(%),M(P25-P75)]
| Item | Low-risk group | Medium-risk group | High-risk group | ||
|---|---|---|---|---|---|
| n | 103 | 156 | 137 | ||
| Gender | Male | 99(96.1) | 112(71.8) | 63(46) | < 0.001 |
| Female | 4(3.9) | 44(28.2) | 74(54) | ||
| In-hospital ventricular fibrillation | 0 | 1(0.6) | 0 | 1.000 | |
| In-hospital ventricular tachycardia | 1(1.0) | 1(0.6) | 1(0.7) | 1.000 | |
| In-hospital atrial fibrillation | 1(1.0) | 4(2.6) | 4(2.9) | 0.637 | |
| In-hospital heart failure | 12(11.7) | 22(14.1) | 36(26.3) | 0.004 | |
| Hypertension | 53(51.5) | 113(72.4) | 85(62.0) | 0.003 | |
| Diabetes | 18(17.5) | 28(17.9) | 33(24.1) | 0.324 | |
| CHD history | 17(16.5) | 24(15.4) | 20(14.6) | 0.838 | |
| Myocardial infarction history | 6(5.8) | 8(5.1) | 14(10.2) | 0.201 | |
| PCI history | 5(4.9) | 6(3.8) | 13(9.5) | 0.109 | |
| Smoking history | 73(70.9) | 85(54.5) | 69(50.4) | 0.004 | |
| Age(years old) | 51.10 ± 8.25 | 61.83 ± 7.50 | 66.63 ± 7.82 | < 0.001 | |
| BMI(kg/m2) | 25.79 ± 4.25 | 24.99 ± 3.27 | 24.91 ± 4.49 | 0.187 | |
| Ejection fraction(%) | 60.95 ± 7.26 | 61.08 ± 9.53 | 51.81 ± 10.23 | < 0.001 | |
| ApoB/ApoA1 | High risk | 2(1.9) | 15(9.6) | 8(5.8) | 0.044 |
| Low risk | 101(98.1) | 141(90.4) | 129(94.1) | ||
| ApoB/ApoA1 | 0.88(0.69–1.01) | 0.95(0.72–1.07) | 0.89(0.71–1.04) | 0.816 | |
| TG(mmol/l) | 1.88(1.07–2.31) | 1.85(1.04–2.26) | 1.51(0.95–1.81) | 0.027 | |
| LDL-c(mmol/l) | 3.06(2..44–3.43) | 3.19(2.49–3.74) | 3.15(2.46–3.72) | 0.372 | |
| Non HDL-c(mmol/l) | 3.51(2.77–4.04) | 3.59(2.85–4.23) | 3.45(2.66–4.03) | 0.465 | |
| Hb(g/L) | 142.91(134–155) | 141.03(131–153) | 138.84(128–152) | 0.249 | |
| PLT(×109/L) | 205.64(172–232) | 202.76(158.25–239) | 201.92(164.5–233) | 0.937 | |
| HCT(L/L) | 0.42(0.39–0.45) | 0.42(0.38–0.45) | 1.65(0.38–0.45) | 0.370 | |
| LM | 7(6.8) | 12(7.7) | 19(13.9) | 0.124 | |
| PLAD | 65(63.1) | 110(70.5) | 102(74.5) | 0.165 | |
| MLAD | 50(48.5) | 87(55.8) | 78(56.9) | 0.397 | |
| RCX | 64(62.1) | 115(73.7) | 110(80.3) | < 0.001 | |
| RCA | 78(75.7) | 134(85.9) | 118(86.1) | 0.086 | |
| RAM | 2(1.9) | 3(1.9) | 0(0.0) | 0.266 | |
| Number of lesions treated | 1.31 ± 0.58 | 1.46 ± 0.71 | 1.50 ± 0.71 | 0.024 | |
| Number of stents implanted | 1.42 ± 0.81 | 1.56 ± 0.97 | 1.56 ± 1.00 | 0.244 | |
| Maximum stent diameter(mm) | 3.34 ± 0.51 | 3.30 ± 0.47 | 3.28 ± 0.47 | 0.584 |
Comparison of MACCE incidence at different time among SYNTAX II low, medium and high-risk group [n(%)]
| Item | Low-risk group | Medium-risk group | High-risk group | |
|---|---|---|---|---|
| MACCE events in hospital | 5(3.3) | 7(3.8) | 16(8.6) | 0.053 |
| MACCE events in 1 year | 19(12.6) | 23(12.5) | 35(18.7) | 0.162 |
| MACCE events in 3 years | 35(23.2) | 52(28.2) | 61(32.8) | 0.150 |
| MACCE events in 5 years | 41(27.2) | 77(41.8) | 73(39.2) | 0.032 |
| Cardiovascular death in hospital | 2(1.3) | 6(3.3) | 7(3.8) | 0.414 |
| Cardiovascular death in 1 year | 4(2.6) | 12(6.5) | 13(7.0) | 0.175 |
| Cardiovascular death in 3 years | 6(4.0) | 13(7.1) | 28(15.1) | 0.001 |
| Cardiovascular death in 5 years | 8(5.3) | 18(9.8) | 41(22.0) | < 0.001 |
| New myocardial infarction in 1 year | 1(0.7) | 1(0.5) | 4(2.1) | 0.389 |
| New myocardial infarction in 3 years | 5(3.3) | 3(1.6) | 6(3.2) | 0.211 |
| New myocardial infarction in 5 years | 9(6.0) | 9(4.9) | 14(7.5) | 0.580 |
| Recurrent revascularization in 1 year | 6(4.0) | 5(2.7) | 6(3.2) | 0.784 |
| Recurrent revascularization in 3 years | 15(9.9) | 13(7.1) | 13(7.0) | 0.530 |
| Recurrent revascularization in 5 years | 22(5.3) | 23(5.4) | 17(9.1) | 0.286 |
| New/aggravated heart failure in 1 year | 2(1.3) | 2(1.1) | 6(3.2) | 0.314 |
| New/aggravated heart failure in 3 years | 3(2.0) | 7(3.8) | 16(8.6) | 0.015 |
| New/aggravated heart failure in 5 years | 4(2.6) | 9(4.9) | 19(10.2) | 0.011 |
| New stroke in 1 year | 2(1.3) | 1(0.5) | 2(1.1) | 0.860 |
| New stroke in 3 years | 4(2.6) | 5(2.7) | 5(2.7) | 1.000 |
| New stroke in 5 years | 5(3.3) | 10(5.4) | 8(4.3) | 0.638 |
Comparison of EQ-5D score at different time among SYNTAX II low, medium and high-risk group [M(P25-P75)]
| Item | Low-risk group | Medium-risk group | High-risk group | |
|---|---|---|---|---|
| EQ-5D score in hospital | 11.58(10.0–13.81) | 10.91(9.24–13.06) | 9.90(9.2–13.76) | 0.196 |
| EQ-5D score in 1 year | 13.28(12.24–14.93) | 12.93(12.24–14.5) | 12.85(12.16–13.82) | 0.508 |
| EQ-5D score in 5 years | 13.19(12.22–15.03) | 12.91(12.16–14.44) | 12.08(10.64–12.92) | 0.001 |
Multivariate logistic regression analysis for in-hospital MACCE events
| Factors | β value | S.E. | Wald χ2 | OR value | OR 95%CI | |
|---|---|---|---|---|---|---|
| ApoB/apoA1 | 0.939 | 0.453 | 4.303 | 0.038 | 2.558(1.053–6.215) | 0.939 |
Multivariate logistic regression analysis for MACCE events in 1 year
| Factors | Control | S.E. | Wald χ2 | OR value | OR 95%CI | |||
|---|---|---|---|---|---|---|---|---|
| SYNTAX score | Medium-risk | Low-risk | 0.753 | 0.325 | 5.387 | 0.02 | 2.124 | 1.124–4.013 |
| High-risk | 2.257 | 0.927 | 5.924 | 0.015 | 9.558 | 1.552–58.865 |
Multivariate logistic regression analysis for MACCE events in 5 years
| Factors | Control | OR 95%CI | ||||||
|---|---|---|---|---|---|---|---|---|
| Previous CHD history | 0.939 | 0.453 | 4.303 | 0.038 | 2.558 | 1.053–6.215 | ||
| Smoking | 0.625 | 0.306 | 4.181 | 0.041 | 1.868 | 1.026–3.402 | ||
| SYNTAX II score | Medium-risk | Low-risk | 1.046 | 0.357 | 8.592 | 0.003 | 2.845 | 1.414–5.725 |
| ApoB/apoA1 | 1.511 | 0.625 | 5.853 | 0.016 | 2.525 | 1.332–5.385 |